Cost‑Share Partnership

Verrica's Japanese development partner, Torii Pharmaceutical, will split the costs of the global Phase 3 program with Verrica on a 50/50 basis. This partnership demonstrates Verrica's commitment to addressing the significant unmet need for common wart treatments worldwide.